Fighting Cancer with Infection, 1891

Now hailed as the father of immunotherapy, William Coley pioneered extraordinary methods to treat cancer.

Written byCatherine Offord
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

CANCER THERAPY PIONEER: William Coley trialed many cancer treatments alongside his immunotherapy toxin. “What’s maybe not so well known is that he helped bring radiation therapy to Memorial Sloan Kettering,” says sociologist David Hess. “That ultimately led to the demise of his own therapy.” Here, Coley is depicted administering radiation therapy in 1902, just seven years after the discovery of X-rays. The hospital’s director, James Ewing, was committed to developing the therapy, and eventually prohibited Coley from using his toxins to treat hospital patients.ROBERT HOKE, COURTESY OF THE MEMORIAL SLOAN KETTERING CANCER CENTER ARCHIVESAt the end of 1890, a young bone surgeon named William Coley watched in despair as an 18-year-old girl died from sarcoma over the course of a few months. “There are certain types of sarcoma that seem almost hopeless from the start, and when surgical skill, if called upon, only proves how utterly powerless it is,” he wrote in a report describing the case.

According to sociologist David Hess of Vanderbilt University, this girl’s death prompted Coley—now known as the father of immunotherapy—to investigate alternatives to surgery in the treatment of cancer. “He looked over hospital records and found a sarcoma patient who had had a bacterial infection,” Hess says. “This patient was alive—seven years later.”

Coley decided to experiment. In the summer of 1891, he began injecting his patients with live (and, later, heat-killed) cultures of streptococcal bacteria, sometimes directly into their tumors. The inoculations induced fevers; then, apparently as a result, some patients’ tumors shrank.

At the time, many researchers “expected that cancer would turn out to be an infectious bacterial disease,” explains Hess. Coley’s treatment made sense—the injected microbes must be killing the pathogens responsible for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile

Published In

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery